Przejdź do zawartości

SRP3165

sTRAIL Receptor-2 (DR5) human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Synonim(y):

DR5, KILER, TNFRSF10B, soluble TRAIL Receptor-2

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok

Informacje o tej pozycji

NACRES:
NA.32
UNSPSC Code:
51111800
Form:
lyophilized
Assay:
≥98% (HPLC), ≥98% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
14.9 kDa
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


biological source

human

recombinant

expressed in E. coli

assay

≥98% (HPLC), ≥98% (SDS-PAGE)

form

lyophilized

potency

1000 ng/mL

mol wt

14.9 kDa

packaging

pkg of 50 μg

technique(s)

cell culture | mammalian: suitable

impurities

<0.1 EU/μg endotoxin, tested

color

white

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... TNFRSF10B(8795)

General description

DR5 (death receptor 5) or TNFRSF10B (tumor necrosis factor receptor superfamily member 10b) is a member of the tumor necrosis factor receptor (TNFR) superfamily. It is a tumor suppressor gene localized to human chromosome 8p and is composed of 10 coding exons. The encoded protein is an integral plasma membrane protein.
Recombinant human sTNFRII is an 18.9 kDa protein (174 amino acid residues) comprising the cysteine rich ligand binding portion of the extracellular domain of the TNFRII protein.

Biochem/physiol Actions

It initiates the formation of death-inducing signal complex (DISC) by recruiting fas-associated death domain (FADD) and caspases to its cytoplasmic death domain (DD). In human lung cancer cells, parthenolide (PTL) induces extrinsic apoptosis by up-regulating TNFRSF10B. Deregulation of this gene results in metastasis, invasion and migration of tumor cells. Mutation leads to loss of p arm in this gene which is frequently the case in head and neck tumors. In a breast cancer xenograft mouse model, DR5 facilitates skeletal metastasis. In prostate carcinoma (PCa) and prostatic intraepithelial neoplasia (PIN), the expression of DR5 is lower in higher grade tumors.

Physical form

Lyophilized with no additives.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

MESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES
Ta strona może zawierać tekst przetłumaczony maszynowo.


Klasa składowania

11 - Combustible Solids

Co się dzieje?

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable



Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów